Statement by Yale University Regarding Bristol-Myers Squibb Company's Program to Fight HIV/AIDS

Yale is pleased that Bristol-Myers Squibb (BMS) has decided to make Zerit, a Yale research discovery, available below cost throughout Africa. The University also commends BMS for the other steps it is taking to help address the AIDS crisis.

Yale worked diligently to remove any obstacles created by its license agreement with BMS. We are gratified that our efforts paved the way for the significant action announced by BMS today. We will continue to encourage all pharmaceutical companies to make their AIDS drugs affordable and widely available in Africa.

Yale is proud that Zerit has helped to prolong the lives of so many who suffer from AIDS. We are especially grateful that BMS’ action will allow many more to benefit from this important drug.